These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 428185)

  • 1. Kinetics and absolute bioavailability of atenolol.
    Mason WD; Winer N; Kochak G; Cohen I; Bell R
    Clin Pharmacol Ther; 1979 Apr; 25(4):408-15. PubMed ID: 428185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker.
    Brown HC; Carruthers SG; Johnston GD; Kelly JG; McAinsh J; McDevitt DG; Shanks RG
    Clin Pharmacol Ther; 1976 Nov; 20(5):524-34. PubMed ID: 10125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atenolol kinetics in renal failure.
    McAinsh J; Holmes BF; Smith S; Hood D; Warren D
    Clin Pharmacol Ther; 1980 Sep; 28(3):302-9. PubMed ID: 7408390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, pharmacology of atenolol and effect of renal disease.
    Wan SH; Koda RT; Maronde RF
    Br J Clin Pharmacol; 1979 Jun; 7(6):569-74. PubMed ID: 465278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Food-induced reduction in bioavailability of atenolol.
    Melander A; Stenberg P; Liedholm H; Scherstén B; Wåhlin-Boll E
    Eur J Clin Pharmacol; 1979 Nov; 16(5):327-30. PubMed ID: 520399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single intravenous dose kinetics accumulation of atenolol in patients with impaired renal function and on hemodialysis.
    Kirch W; Schäfer M; Braun M
    Arch Toxicol Suppl; 1980; 4():366-9. PubMed ID: 6933939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of atenolol--a review.
    Kirch W; Görg KG
    Eur J Drug Metab Pharmacokinet; 1982; 7(2):81-91. PubMed ID: 6749509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atenolol interaction with aspirin, allopurinol, and ampicillin.
    Schäfer-Korting M; Kirch W; Axthelm T; Köhler H; Mutschler E
    Clin Pharmacol Ther; 1983 Mar; 33(3):283-8. PubMed ID: 6825385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of atenolol in relation to renal function.
    Kirch W; Köhler H; Mutschler E; Schäfer M
    Eur J Clin Pharmacol; 1981 Jan; 19(1):65-71. PubMed ID: 7461026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with atenolol in patients with chronic liver disease.
    Kirch W; Schäfer-Korting M; Mutschler E; Ohnhaus EE; Braun W
    J Clin Pharmacol; 1983 Apr; 23(4):171-7. PubMed ID: 6863581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the pharmacokinetics and pharmacodynamics of atenolol in man.
    Fitzgerald JD; Ruffin R; Smedstad KG; Roberts R; McAinsh J
    Eur J Clin Pharmacol; 1978 May; 13(2):81-9. PubMed ID: 658112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic properties of ethosuximide in monkeys. I. Single-dose intravenous and oral administration.
    Patel IH; Levy RH; Bauer TG
    Epilepsia; 1975 Dec; 16(5):705-16. PubMed ID: 816644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.
    Flouvat B; Decourt S; Aubert P; Potaux L; Domart M; Goupil A; Baglin A
    Br J Clin Pharmacol; 1980 Apr; 9(4):379-85. PubMed ID: 7378254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability of atenolol formulations.
    Mcainsh J; Simpson WT; Holmes BF; Young J; Ellis SH
    Biopharm Drug Dispos; 1980; 1(6):323-32. PubMed ID: 7459427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of pretreatment with cimetidine on the bioavailability and disposition of atenolol and metoprolol.
    Houtzagers JJ; Streurman O; Regårdh CG
    Br J Clin Pharmacol; 1982 Jul; 14(1):67-72. PubMed ID: 6125199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent.
    Ishizaki T; Ohnishi A; Sasaki T; Kushida K; Horai Y; Chiba K; Suganuma T
    Eur J Clin Pharmacol; 1983; 25(1):95-101. PubMed ID: 6137389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absolute bioavailability of chlorthalidone in man: a cross-over study after intravenous and oral administration.
    Fleuren HL; Thien TA; Verwey-van Wissen CP; van Rossum JM
    Eur J Clin Pharmacol; 1979 Feb; 15(1):35-50. PubMed ID: 421727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of inflammatory disease on the clinical pharmacokinetics of atenolol and metoprolol.
    Kirch W; Spahn H; Ohnhaus EE; Köhler H; Heinz U; Mutschler E
    Biopharm Drug Dispos; 1983; 4(1):73-81. PubMed ID: 6839004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of exercise on renal clearance of atenolol.
    Mason WD; Kochak G; Winer N; Cohen I
    J Pharm Sci; 1980 Mar; 69(3):344-5. PubMed ID: 7381717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability in man of atenolol and chlorthalidone from a combination formulation.
    McAinsh J; Bastain W; Young J; Harry JD
    Biopharm Drug Dispos; 1981; 2(2):147-56. PubMed ID: 7248478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.